Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew R Blight

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Clinical Therapeutics|November 20, 2009
Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up studyTimothy Vollmer, Andrew R Blight, Herbert R Henney
Journal of Neurotrauma|June 16, 2006
4-chloro-3-hydroxyanthranilate reduces local quinolinic acid synthesis, improves functional recovery, and preserves white matter after spinal cord injuryJennifer R Yates, Melvyn P Heyes, Andrew R Blight
Clinical Therapeutics|April 14, 2012
The safety profile of dalfampridine extended release in multiple sclerosis clinical trialsDavid R Cornblath, E Jay Bienen, Andrew R Blight
Neurology|March 29, 2013
Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MSJeremy Hobart, Andrew R Blight, Andrew Goodman, et al.
Journal of Neurotrauma|February 18, 2005
Chondroitinase ABCI improves locomotion and bladder function following contusion injury of the rat spinal cordAnthony O Caggiano, Michael P Zimber, Anindita Ganguly, et al.
International Journal of MS Care|October 23, 2014
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosisAndrew D Goodman, Theodore R Brown, Randall T Schapiro, et al.
Archives of Physical Medicine and Rehabilitation|February 19, 2004
Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injuryKeith C Hayes, Patrick J Potter, Jane T Hsieh, et al.
Journal of Clinical Pharmacology|October 24, 2013
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label studyEmil Samara, Peter Winkle, Patricia Pardo, et al.
Topics in Spinal Cord Injury Rehabilitation|August 14, 2024
Data Safety Monitoring Boards: Overview of Structure and Role in Spinal Cord Injury StudiesAndrew R Blight, James D Guest, James Hamer, et al.
Clinical Therapeutics|November 14, 2015
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled TrialAngela Applebee, Andrew D Goodman, Angeli S Mayadev, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Clinical Therapeutics|November 20, 2009
Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up studyTimothy Vollmer, Andrew R Blight, Herbert R Henney
Journal of Neurotrauma|June 16, 2006
4-chloro-3-hydroxyanthranilate reduces local quinolinic acid synthesis, improves functional recovery, and preserves white matter after spinal cord injuryJennifer R Yates, Melvyn P Heyes, Andrew R Blight
Clinical Therapeutics|April 14, 2012
The safety profile of dalfampridine extended release in multiple sclerosis clinical trialsDavid R Cornblath, E Jay Bienen, Andrew R Blight
Neurology|March 29, 2013
Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MSJeremy Hobart, Andrew R Blight, Andrew Goodman, et al.
Journal of Neurotrauma|February 18, 2005
Chondroitinase ABCI improves locomotion and bladder function following contusion injury of the rat spinal cordAnthony O Caggiano, Michael P Zimber, Anindita Ganguly, et al.
International Journal of MS Care|October 23, 2014
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosisAndrew D Goodman, Theodore R Brown, Randall T Schapiro, et al.
Archives of Physical Medicine and Rehabilitation|February 19, 2004
Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injuryKeith C Hayes, Patrick J Potter, Jane T Hsieh, et al.
Journal of Clinical Pharmacology|October 24, 2013
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label studyEmil Samara, Peter Winkle, Patricia Pardo, et al.
Topics in Spinal Cord Injury Rehabilitation|August 14, 2024
Data Safety Monitoring Boards: Overview of Structure and Role in Spinal Cord Injury StudiesAndrew R Blight, James D Guest, James Hamer, et al.
Clinical Therapeutics|November 14, 2015
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled TrialAngela Applebee, Andrew D Goodman, Angeli S Mayadev, et al.
Pageof 4